Trial Profile
A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Glioblastoma; Glioma; Meningioma
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 25 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 06 Mar 2023 Planned End Date changed from 1 Nov 2022 to 1 Jan 2024.
- 06 Mar 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Apr 2023.